


THAT WHICH IS CLAIMED IS:

- 5-18 Aug 4  
A
1. A compound according to Formula I:



wherein:

$R_1$ ,  $R_2$ ,  $R_3$  and  $R_4$  are each independently selected from the group consisting of H, alkyl, alkoxy, halide, and alkylhalide groups;

$R_5$  is H, alkyl or aryl;

$R_6$  is H, alkyl, aryl, or  $NR_7R_8$ , wherein  $R_7$  and  $R_8$  are each independently selected from the group consisting of H, alkyl and aryl; and

$X$  is O, S or  $NR_9$ , wherein  $R_9$  is H or alkyl.


2. The compound according to Claim 1, wherein  $R_1$  and  $R_2$  are each an H.
3. The compound according to Claim 1, wherein  $R_1$  and  $R_2$  are each an H and  $R_3$  and  $R_4$  are each lower alkyls.
4. The compound according to Claim 1, wherein  $R_3$  and  $R_4$  are each a halide.
5. The compound according to Claim 1, wherein  $R_3$  and  $R_4$  are each alkoxy.
6. The compound according to Claim 1, wherein  $R_3$  and  $R_4$  are each alkyl halides.
7. The compound according to Claim 1, wherein  $R_5$  is an H,  $R_6$  is a  $NR_7R_8$ , and  $R_7$  and  $R_8$  are each an H.
8. The compound according to Claim 1, wherein  $R_6$  is a pyridyl.

9. The compound according to Claim 1, wherein  $R_6$  is a substituted pyridyl.

10. The compound according to Claim 1, wherein  $R_6$  is a quinolinyl.

11. A pharmaceutical composition comprising a compound according to Formula

I:



wherein:

$R_1$ ,  $R_2$ ,  $R_3$  and  $R_4$  are each independently selected from the group consisting of H, alkyl, alkoxy, halide, and alkylhalide groups;

$R_5$  is H, alkyl or aryl;

$R_6$  is H, alkyl, aryl, or  $NR_7R_8$ , wherein  $R_7$  and  $R_8$  are each independently selected from the group consisting of H, alkyl and aryl; and

X is O, S or  $NR_9$ , wherein  $R_9$  is H or alkyl;

in a pharmaceutically acceptable carrier.

12. The pharmaceutical composition of Claim 11, wherein the composition is formulated for parenteral administration.


13. The pharmaceutical composition of Claim 11, wherein the composition is formulated for oral administration.

14. The pharmaceutical composition of Claim 11, wherein the composition is formulated for topical administration.

15. A process for preparing a pharmaceutical composition comprising formulating the compound of the formula (I) according to claim 1 and optionally a pharmaceutically utilizable carrier.

SEE ANDX  
G

16. A method of treating an microbial infection in a subject in need of such treatment, wherein the microbial infection is caused by a microorganism selected from the group consisting of *Mycobacterium tuberculosis*, *Trypanosoma* spp., *Candida albicans*, *Aspergillus* spp., *Cryptosporidium parvum*, *Giardia lamblia*, *Plasmodium* spp., *Pneumocystis carinii*, *Toxoplasma gondii*, *Fusarium solani*, and *Cryptococcus neoformans*, said method comprising administering to the subject a compound according to Formula I or a pharmaceutically acceptable salt thereof:



wherein:

wherein  $R_1$ ,  $R_2$ ,  $R_3$  and  $R_4$  are each independently selected from the group consisting of H, alkyl, alkoxy, halide, and alkylhalide groups;

$R_5$  is H, alkyl or aryl;

$R_6$  is H, alkyl, aryl, or  $NR_7R_8$ , wherein  $R_7$  and  $R_8$  are each independently selected from the group consisting of H, alkyl and aryl; and

X is O, S or  $NR_9$ , wherein  $R_9$  is H or alkyl.

17. The method according to Claim 16, wherein the compound is administered parenterally.

18. The method according to Claim 16, wherein the compound is administered orally.

19. The method according to Claim 16, wherein the compound is administered topically.